您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (12): 33-38.doi: 10.6040/j.issn.1671-7554.0.2018.466

• • 上一篇    

山东大学齐鲁医院金黄色葡萄球菌血流感染发生率、菌株耐药性、抗菌药物使用及预后变化

崔毅1,尹梅2,李伟3,李远1,韩辉1,单悌超1,岳金凤1,丁士芳1,李琛1,陈晓梅1,吴大玮1,王昊1   

  1. 山东大学齐鲁医院 1.重症医学科;2.老年病科;3.检验医学科, 山东 济南 250012
  • 发布日期:2022-09-27
  • 通讯作者: 王昊. E-mail:wanghao34@126.com
  • 基金资助:
    国家自然科学基金(81501786);山东省自然科学基金(ZR2017PH050);山东省医药卫生科技发展计划(2015WS0291);济南市临床医学科技创新计划(201503010)

Changes of the incidence, antibiotic resistance, antibiotic therapy and prognosis in patients with Staphylococcus aureus bloodstream infection in Qilu Hospital of Shandong University

CUI Yi1, YIN Mei2, LI Wei3, LI Yuan1, HAN Hui1, SHAN Tichao1, YUE Jinfeng1, DING Shifang1, LI Chen1, CHEN Xiaomei1, WU Dawei1, WANG Hao1   

  1. 1. Intensive Care Unit;
    2. Department of Geriatrics;
    3. Department of Laboratory, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-09-27

PDF (PC)

34

摘要： 目的 探讨近年来山东大学齐鲁医院金黄色葡萄球菌血流感染(SABI)发生率、菌株耐药性、抗菌药物治疗及预后转归的变化情况。 方法 回顾性分析2009年1月至2010年12月、2015年1月至2016年12月入住山东大学齐鲁医院并发生SABI的患者资料(分别为17、32例,作为甲组、乙组),采集病原学、实验室及临床指标,计算SABI发生时急性生理与慢性健康II(APACHEⅡ)评分和序贯脏器衰竭评分(SOFA),比较不同年度SABI的发生率、菌株耐药率、抗菌药物治疗情况、病情转归和28d病死率。 结果 与2009至2010年相比,2015至2016年SABI发生率(1.5 vs 1.1)、28 d病死率(29.1% vs 18.8%)均下降,但差异无统计学意义(P均>0.05);患者的一般情况(性别、年龄、住院时间、科室分布、基础疾病)、住院花费、原发感染灶和病情严重程度(机械通气、肾脏替代治疗比例、感染性休克发生率及APACHE II、SOFA评分)等指标差异均无统计学意义(P均>0.05)。与2009至2010年相比,2015至2016年SABI患者所分离的致病菌中耐甲氧西林金黄色葡萄球菌(MRSA)所占比例升高,但差异无统计学意义(P>0.05),对青霉素、环丙沙星、万古霉素、利奈唑胺等的耐药率差异均无统计学意义(P均>0.05),无万古霉素、利奈唑胺耐药株出现;在目标性抗菌治疗中,糖肽类抗菌药物使用率显著提高(χ2=5.244,P=0.022),而β内酰胺类抗菌药物使用率显著下降(χ2=4.895,P=0.027)。 结论 近8年来,山东大学齐鲁医院SABI的发生率和28 d病死率呈下降趋势,但MRSA分离率升高,糖肽类抗菌药物使用愈加普及。

关键词: 金黄色葡萄球菌, 血流感染, 抗菌药物, 细菌耐药性, 预后

Abstract: Objective To investigate the changes of the incidence, antibiotic resistance, antibiotic therapy and prognosis in patients with Staphylococcus aureus bloodstream infection(SABI)in Qilu Hospital of Shandong University in recent 山 东 大 学 学 报 (医 学 版)56卷12期 -崔毅,等. 山东大学齐鲁医院金黄色葡萄球菌血流感染发生率、菌株耐药性、抗菌药物使用及预后变化 \=-years. Methods The basic information of patients with SABI were retrospectively collected from January 2009 to December 2010(17 cases, A group)and from January 2015 to December 2016(32 cases, B group). The pathogen, laboratory and clinical data were also collected. Acute Physiology and Chronic Health Evaluation II(APACHEⅡ)score and Sequential Organ Failure Assessment(SOFA)score were then calculated. The incidence of SABI, the incidence of antibiotic resistance, antibiotic treatment, patient outcome and 28-day mortality were compared between these two groups. Results Compared with A group, the incidence and 28-day mortality of SABI in B group decreased(1.5 vs 1.1; 29.1% vs 18.8%)with no statistical difference(both P>0.05)in our hospital. The difference between the two groups in the basic information of SABI patients(including sex, age, length of stay, distribution of departments and primary diseases), hospitalization cost, primary source of bloodstream, and the severity of illness(including the rate of mechanical ventilation and renal replacement therapy, the incidence of septic shock, APACHE II score and SOFA score)were not statistically significant(all P>0.05). The proportion of methicillin-resistant Staphylococcus aureus(MRSA)in isolates increased with no statistical difference(P>0.05). The resistance rates of the isolates to penicillin, ciprofloxacin, vancomycin and linazolamide did not differ significantly(all P>0.05). No vancomycin or linezolid resistant strains were found in the both groups. The patients in A group received significantly more antibiotic therapy of glycopeptide antibiotics and less antibiotic therapy of β-lactamase antibiotics for targeted antimicrobial therapy compared with B group(χ2=5.244,P=0.022; χ2=4.895,P=0.027). Conclusion In the recent 8 years, the incidence and 28-day mortality of SABI decreased, while the isolation proportion of MRSA increased in Qilu Hospital of Shandong University. The usage of glycopeptide antibiotics was more and more common.

Key words: Staphylococcus aureus, Bloodstream infection, Antibiotics, Bacterial resistance, Prognosis

中图分类号: 

  • R515
[1] Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies[J]. Clin Infect Dis, 2009, 48(Suppl 4): S231-S237.
[2] EARSS Management Team. European Antimicrobial Resistance Surveillance System annual report 2007[M]. Bilthoven: European Center for Disease Prevention and Control, 2008: 48-53.
[3] Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment[J]. Crit Care, 2017, 21(1): 211. doi: 10.1186/s13054-017-1801-3.
[4] Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremia[J]. Infect Chemother, 2016, 48(4): 267-273.
[5] Khatib R, Sharma M, Iyer S, et al. Decreasing incidence of Staphylococcus aureus bacteremia over 9 years: greatest decline in community-associated methicillin-susceptible and hospital-acquired methicillin-resistant isolates[J]. Am J Infect Control, 2013, 41(3): 210-213.
[6] de Oliveira Conterno L, Wey SB, Castelo A. Staphylococcus aureus bacteremia: comparison of two periods and a predictive model of mortality[J]. Braz J Infect Dis, 2002, 6(6): 288-297.
[7] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5): 314-320.
[8] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013, 41(2): 580-637.
[9] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing-Twenty-Sixth Informational Supplement[S]. 2016.
[10] Reddy PN, Srirama K, Dirisala VR. An update on clinical burden, diagnostic tools, and therapeutic options of Staphylococcus aureus[J]. Infect Dis(Auckl), 2017, 10: 1179916117703999. doi: 10.1177/1179916117703999.
[11] Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management[J]. Clin Microbiol Rev, 2015, 28(3): 603-661.
[12] Asgeirsson H, Gudlaugsson O, Kristinsson KG, et al. Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality[J]. Clin Microbiol Infect, 2011, 17(4): 513-518.
[13] Benfield T, Espersen F, Frimodt-Moller N, et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000[J]. Clin Microbiol Infect, 2007, 13(3): 257-263.
[14] El Atrouni WI, Knoll BM, Lahr BD, et al. Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population-based study[J]. Clin Infect Dis, 2009, 49(12): e130-138.
[15] Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004, 39(3): 309-317.
[16] 高婧,李伟,王昊,等.重症监护病房鲍曼不动杆菌血流感染发生率、菌株耐药性、抗菌药物使用及预后分析[J]. 中华传染病杂志, 2017, 35(4): 232-234.
[17] Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014[J]. Clin Microbiol Infect, 2016, 22(Suppl 1): S9-S14.
[18] 耐甲氧西林金黄色葡萄球菌感染防治专家委员会.耐甲氧西林金黄色葡萄球菌感染防治专家共识2011年更新版[J]. 中华实验和临床感染病杂志, 2011, 5(3): 66-72.
[19] 邹启富,闵文静,范文.医院感染金黄色葡萄球菌的分布与耐药性调查[J].中华医院感染学杂志, 2009, 19(16): 2179-2180. ZOU Qifu, MIN Wenjing, FAN Wen. Clinical distribution and drug-resistance in nosocomial infections with Staphylococcus aureus[J]. Chinese Journal of Nosocomiology, 2009, 19(16): 2179-2180.
[20] 申黎艳,李慧,万胜平,等.2012~2013年金黄色葡萄球菌临床分布及耐药性[J].中国老年学杂志, 2017, 37(9): 2260-2262.
[21] Mera RM, Suaya JA, Amrine-Madsen H, et al. Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion[J]. Microb Drug Resist, 2011, 17(2): 321-328.
[22] 陈燕,刘昆,郝素云,等.2005—2009年医院主要病原菌耐药趋势分析[J].中华医院感染学杂志, 2011, 21(5): 975-977. CHEN Yan, LIU Kun, HAO Suyun, et al. Drug resistance tendency of major pathogenic bacteria during 2005-2009[J]. Chinese Journal of Nosocomiology, 2011, 21(5): 975-977.
[23] 朱吉超,魏莲花,杨永清,等.耐甲氧西林金黄色葡萄球菌临床分布及耐药性分析[J].中华医院感染学杂志, 2017, 27(7): 1462-1465. ZHU Jichao, WEI Lianhua, YANG Yongqing, et al. Clinical distribution and drug resistance of methicillin-resistant Staphylococcus strains[J]. Chinese Journal of Nosocomiology, 2017, 27(7): 1462-1465.
[24] Tacconelli E, De Angelis G, Cataldo MA, et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA)isolation? A systematic review and meta-analysis[J]. J Antimicrob Chemother, 2008, 61(1): 26-38.
[25] Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections[J]. Clin Infect Dis, 2007, 45(Suppl 3): S191-S195.
[26] Tarai B, Das P, Kumar D. Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options[J]. J Lab Physicians, 2013, 5(2): 71-78.
[27] Vellappally S, Divakar DD, Al Kheraif AA, et al. Occurrence of vancomycin-resistant Staphylococcus aureus in the oral cavity of patients with dental caries[J]. Acta Microbiol Immunol Hung, 2017, 64(3): 343-351.
[28] 刘杰,韩嘉静,康熙雄,等.2010-2016年临床分离金黄色葡萄球菌的耐药性分析[J].检验医学与临床, 2017, 14(23): 3428-3430. LIU Jie, HAN Jiajing, KANG Xixiong, et al. Analysis on drug resistance of Staphylococcus aureus between 2010 and 2016[J]. Lab Med Clin, 2017, 14(23): 3428-3430.
[1] 郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[2] 王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[3] 高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[4] 贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[5] 张玉凤,徐敏,邢秀丽,逄曙光,户克庆. 689例非ST段抬高型心肌梗死患者的临床流行病学特征[J]. 山东大学学报 (医学版), 2022, 60(7): 118-122.
[6] 李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[7] 郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[8] 安袁笑雪,杜以明,田甜,张一,薛玉文. 肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 59-63.
[9] 李燕,刘静,李娟,杨秋红. 50例孕产妇血流感染临床特征及胎盘病理分析[J]. 山东大学学报 (医学版), 2022, 60(1): 48-54.
[10] 陈立晓,英信江,陈歆维,王菲,孙臻峰,董频. 下咽鳞癌蛋白质谱鉴定及预后靶分子筛选[J]. 山东大学学报 (医学版), 2021, 59(9): 140-147.
[11] 褚晏,刘端瑞,朱文帅,樊荣,马晓丽,汪运山,郏雁飞. DNA甲基化转移酶在胃癌中的表达及其临床意义[J]. 山东大学学报 (医学版), 2021, 59(7): 1-9.
[12] 陈丽宇,肖娟,吕仙忠,段宝敏,洪凡真. 影响孕产妇下肢深静脉血栓预后的危险因素分析[J]. 山东大学学报 (医学版), 2021, 59(7): 38-42.
[13] 田瑶天,王宝,李叶琴,王滕,田力文,韩波,王翠艳. 基于可解释性心脏磁共振参数的机器学习模型预测儿童心肌炎的预后[J]. 山东大学学报 (医学版), 2021, 59(7): 43-49.
[14] 李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[15] 米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发